What I have: 15 mg · dulaglutide.
I can predict the outcome but I cannot explain it, which means I will get the next case wrong.
I would like to know how confident the field actually is about this.
So what is the mechanism, and how well established is it?
Two administrations of 7.5 mg instead of one of 15 mg — the same 15 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 15 ÷ 2 = 7.5. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
The relevant arithmetic is the accumulation ratio, which tells you how flat the profile already is at the current interval.
For a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|---|---|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
Stated carefully, for a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
More injections means more handling risk, and that cost is certain while the benefit is not.
If you cannot read half the dose accurately, you cannot split it accurately.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsTo be exact about it, if the goal is tolerability, a slower titration has better evidence behind it than a split schedule.
Accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
A slower titration achieves a lower peak exposure with fewer handling steps, which is why it is the better-evidenced answer to the same problem.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
Halving a dose you cannot read accurately introduces an error larger than the effect you are chasing.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
edited 4 Aug 2026 by esben_lykke — added the citation requested in comments
Start with the half-life. For an agent with a one-week half-life, weekly dosing already produces a nearly flat profile and splitting changes very little.
Each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
In practice, reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
Published half-lives for the agents in this class range from about thirteen hours to about a week, which is the range over which the answer changes.
The caveat is that no split schedule has been evaluated in a trial, so the whole discussion is inference plus report.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
On the detail: every split doubles the number of stopper entries and injections, which is a real cost against an uncertain benefit.
Splitting that same weekly dose into two half-doses at 3.5-day intervals gives τ/t½ = 0.5 and a peak-to-trough ratio of about 1.41. The profile is flatter, and the difference between a 2-fold and a 1.4-fold swing is not obviously perceptible.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Every split is another stopper entry. Count that cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.